The primary objective of this study was to evaluate the safety of infusion of CD34 + cells, selected using a clinical scale magnetically activated cell sorting device, assessed by time to hematological engraftment and incidence of adverse events. Secondary objectives included evaluation of device performance in terms of purity and recovery of the CD34 + cell product. Breast cancer patients suitable for transplantation received cyclophosphamide and filgrastim for mobilisation, followed by three leukaphereses. The products of the first two leukaphereses underwent CD34
these cells may contribute to relapse following transplantation. [3] [4] [5] One strategy for the reduction of the tumor cell burden is CD34 + cell selection and a variety of methods, including antibody-antigen interaction followed by immuno-magnetic bead adsorption and column adsorption, are currently available for clinical application. [6] [7] [8] [9] [10] Here we describe the results of a clinical study using magnetically activated cell sorting (MACS) techniques for the isolation of CD34 + cells. MACS techniques utilize antibody-antigen interactions and high gradient magnetic fields to select target cells from heterogeneous cell populations. Antibodies directed against cell surface antigens are covalently conjugated to superparamagnetic microbeads made of an iron-dextran complex. 11, 12 When mixed with a cell population containing the appropriate target cells and passed through a high gradient magnetic field, the antibody conjugate causes the target cells to be retained in the field. Removal of the field allows the target cells to be eluted and collected.
A potential application of MACS is the selection of CD34 + cells from bone marrow and leukapheresis harvests. When used in this setting, research scale devices have shown performance in terms of purity and recovery which is either comparable with or superior to other technologies. 13 A fully automated clinical scale system (CliniMACS, AmCell, CA, USA) utilising MACS technology has been developed. Pre-clinical testing has demonstrated that the system produces a highly pure CD34
+ cell population and is capable of processing the large numbers of cells present in leukapheresis products. 14 
Reported here are the results of a clinical trial in which CD34
+ cells isolated using the CliniMACS system, were infused into breast cancer patients to provide hematopoietic autograft support following high-dose chemotherapy. The primary objective of the study was to evaluate the safety of infusion of the selected CD34 + cells as assessed by the time to hematological engraftment and incidence of adverse events. The secondary objectives were to evaluate the performance of the clinical device as measured by assessment of purity, recovery, viability and microbiological contamination of the CD34 + cell product as well as long-term engraftment, immune-reconstitution and production of human antimouse antibodies (HAMA).
Patients and methods

Study design and patient eligibility
This was a multi-center, single-arm, safety study. The study scheme is illustrated in Figure 1 . Patients underwent mobilization and three leukaphereses followed by treatment with high-dose chemotherapy and infusion of selected CD34 + cells. On completion of the treatment phase, patients were followed up for a further 100 days.
Patients could be enrolled if they had histologically proven breast cancer stage II-IV; were aged 18-65 (inclusive) with a Karnofsky performance status of at least 80%; had normal hematology and biochemistry and had given written informed consent.
Major exclusion criteria were stage II or III disease treated with more than six cycles of prior adjuvant chemotherapy; stage IV disease treated with prior adjuvant chemotherapy, completed less than 12 months prior to the study start and/or treated with an additional course of chemotherapy, composed of more than six cycles; prior treatment with murine monoclonal antibodies; history of severe allergies requiring medical treatment or known allergy to iron-dextran and active inflammatory disease or a history of asthma requiring medical treatment.
Mobilization regimen and leukapheresis
The mobilization regimen consisted of cyclophosphamide (500 mg/m 2 i.v.), 5-fluorouracil (500 mg/m 2 i.v.), and epirubicin (90 mg/m 2 i.v.) on the first day followed by filgrastim (10 g/kg/day) administered daily until completion of the second leukapheresis.
The first leukapheresis took place on the first day, postnadir, when the WBC was у2.0 × 10 9 /l or when the peripheral blood CD34
+ count was у20 × 10 leukaphereses were then carried out on consecutive days. Leukaphereses were performed according to standard practice at each treating institution. The products of each of the first two leukaphereses individually underwent CD34
+ cell selection using the Clini-MACS system. The third was retained, unselected, as the 'back-up' product.
Fluorescence activated cell sorting (FACS) analysis of CD34 + cell numbers before and after selection was carried out at a central laboratory and locally at each treating institution. The central laboratory results were used to assess device performance, in terms of purity and recovery of the CD34 + cell population. The institutional analyses were used to make clinical decisions about the future treatment of patients. There was no attempt to standardize methods of analysis among the treating institutions.
CD34
+ cell selection
+ selection was performed immediately after the leukapheresis product had been collected. The leukapheresis product was transferred to a 600 ml transfer pack (Baxter Healthcare Corporation, Fenwal Division, Deerfield, IL, USA) and brought to a standard volume of 95 ml by centrifugation and removal of excess plasma or by the addition of phosphate-buffered saline (PBS) containing 0.5% human serum albumin and 1 mm EDTA. It was then incubated for 30 min at room temperature with 7.5 ml of murine anti-CD34 antibody (AC 101) conjugated to iron-dextran microbeads (AmCell). The product was then washed twice in PBS to remove excess antibody reagent.
The CliniMACS system was operated according to the manufacturer's instructions. The tubing set, including separation columns and a microaggregate blood transfusion filter (Pall Biomedical Incorporated, Fajardo, Puerto Rico)
+ cells provide rapid engraftment after HD chemotherapy DJ Richel et al 245 was affixed to the CliniMACS system. Under microprocessor control the tubing set was flushed with PBS to remove air bubbles from the separation columns. The 600 ml transfer pack containing the antibody-labelled cells was then attached to the microaggregate blood filter and hung on the CliniMACS system. CD34
+ cell selection was carried out, again under direct microprocessor control. The CD34
+ selection was concluded in approximately 30 min and the CD34 + cells were eluted into a cell collection bag attached to the tubing set. The total volume of the selected cells was approximately 45 ml, which, after aseptic collection of samples for analysis, was sent for cryopreservation.
Central laboratory CD34
+ cell analysis and assessment of system performance FACS analysis performed at the central laboratory was used to assess device performance in terms of the purity and recovery of the CD34 + population. The details of the methods used have been described previously.
14,15 Cells were stained with CD45-FITC and IgG1-PE as the control or CD45-FITC and CD34-PE as the test. A gate was established around the WBC using CD45-FITC vs side scatter to eliminate particles of debris and unwanted cells such as platelets. The percentage of CD34 + cells was calculated by the total number of CD34-positive events with low side scatter over the total events in the CD45-FITC vs side scatter gate. Following a similar calculation with the control sample, the control value was then subtracted from this value.
Having determined the number of CD34 + cells in the leukapheresis products the percentage purity of selected CD34
+ cells was calculated as:
purity (%) = total number of CD34 + cells after selection total number of cells after selection × 100
The percentage recovery of selected CD34 + cells was calculated as:
Performance of the CliniMACS system was also assessed by cell viability (trypan blue exclusion) and microbiological contamination (routine blood culture) before and after cell selection. All these assessments were performed at the local laboratories.
Cryopreservation
All products were cryopreserved according to standard practice at each treating institution.
High-dose chemotherapy regimen and transplantation procedure
Patients began treatment as soon as possible after the last leukapheresis with a maximum of 30 days between the last + cells in the combined selected products was у2.0 × 10 6 /kg patient body weight, only selected products were infused; if the total number of CD34 + cells in the selected products was Ͻ2.0 × 10 6 /kg patient body weight, but the total number of CD34 + cells in all three products (selected and the 'back-up') was у1.0 × 10 6 /kg, selected products were infused followed by the 'back-up' product 24 h later; if the total number of cells available was Ͻ1.0 × 10 6 /kg, then the patient was withdrawn from the study and treated according to the discretion of the investigator.
Platelet transfusion and antibiotic therapy were administered according to standard practice at each treating institution.
Administration of filgrastim, 10 g/kg/day s.c., began 24 h after the last cell infusion and continued until neutrophil engraftment had occurred. This was defined as a neutrophil count of у1.0 × 10 9 /l for 3 days or у10 × 10 9 /l for 1 day. Blood samples were taken until hematological recovery was confirmed (defined as an unsupported platelet count of у20 × 10 9 /l for 3 consecutive days and an absolute neutrophil count of у0.5 × 10 9 /l for 3 consecutive days). Samples were also taken at 28, 60 and 100 days postinfusion blood samples for routine biochemistry and to assess hematological and immune status and presence of HAMA.
Immune status was assessed by FACS analysis of CD4 and CD8 lymphocyte subsets at the individual clinical sites. HAMA to mouse IgG were evaluated, centrally, by a solid phase radio-immunoassay.
Results
Sixty-five patients were recruited into the study from three European sites. Of the 65 patients who were recruited into the study, 63 provided leukapheresis products for selection and 60 progressed to treatment with high-dose chemotherapy. Five patients were withdrawn from the study prior to infusion of selected cells. The reasons for withdrawal were two cases of poor mobilization, one death, one case of renal insufficiency and one patient withdrew consent. Of the 60 patients who received high-dose chemotherapy, 54 received selected products only, while six received selected cells and the 'back-up' product on the following day. Baseline and demographic data for all patients are presented in Table 1 .
A total of 126 samples were sent to the central laboratory for analysis. However, one pre-selection sample and two post-selection samples could not be analyzed due to technical and logistical problems. Before selection the median number of cells per product was 203. System performance data are presented graphically in Figures 2 and 3 .
The median cell viability before selection was 96.7% (range 60.0-100.0%) and 96.7% (range 53.0-100.0%) after selection. Samples from 123 leukapheresis products were assessed for microbiological contamination before selection and samples from 122 products were available for assessment after selection. Samples from two leukapheresis products assessed before selection were found to be contaminated. In one case, the CD34 − fraction assessed following selection was found to be contaminated, but no culture was grown from the selected product. In the other case, no cul- ture was grown from the CD34 − fraction following selection and the selected product was not examined.
Thirteen device malfunctions from 126 selection runs were reported. Cell separation was aborted in seven instances. In all cases where malfunctions occurred, sufficient CD34 + cells were available to support engraftment, although recovery may have been reduced. These were prototype devices and resolution measures have been identified and introduced to prevent recurrence.
Fifty-four patients received selected products only. The median time to unsupported platelet recovery was 11.0 days (range 5.0-51.0 days, Table 2, Figure 4 ) in this group, with the median time to neutrophil recovery being 9.0 days Figure 5 ). The time to hematological engraftment was censored for two patients. One patient died 5 days after infusion of selected products before experiencing either platelet or neutrophil recovery. One patient received the 'back-up' product approximately 6 weeks after infusion of selected products due to failure to recover her platelet counts. Following infusion of the 'back-up' product the patient continued to be thrombocytopenic, requiring transfusion support.
For the six patients who received selected cells and the 'back-up' product on the following day, the times to unsupported platelet recovery were 9, 11, 16, 13, 21 and 31 days and the times to neutrophil recovery were 10, 8, 10, 10, 9 and 10 days.
There were two deaths reported during the study. One patient died of pulmonary hemorrhage during mobilization and the second died of ARDS and septicaemia 5 days after infusion of selected cells. Neither of the two deaths was reported as being associated with selection procedures or infusion of selected cells.
There were no adverse events reported as related to infusion of selected products. The adverse event profile was typical of a patient population undergoing cytotoxic chemotherapy and treatment with filgrastim (eg alopecia, bone pain and gastrointestinal disorders). There were no reports suggesting any significant hypersensitivity reactions or reactions to the iron-dextran in the antibody conjugate. One patient developed Quinke's oedema immediately after a platelet transfusion 5 days after selected cell infusion. Three patients reported mild or moderate skin rash starting between 3 and 27 days after selected cell infusion. These events were considered not related to selected cell infusion by clinical investigators.
All patients completed 60 and 100 day follow-ups after infusion, during which time their hematological and immune status was monitored, as was HAMA production. There were no reports of late engraftment failure defined either as the need for additional blood transfusions or use of the 'back-up' leukapheresis product after engraftment had occurred, while patterns for recovery of CD4 + and CD8 + cells were typical of a transplant population (Table 3) . No patients were reactive for HAMA. 
Discussion
MACS technology uses the antibody-antigen interaction and magnetic field forces to isolate target cells from heterogeneous cell populations. It can be used in a variety of cell types 12 with CD34 + cell selection in the transplant setting being a potentially important area of application.
Kato and Radbruch 11 reported on the use of MACS technology as a mechanism for isolating CD34 + cells. Peripheral blood obtained from healthy volunteers and centrifuged over Ficoll-Paque was used as the source of mononuclear cells which were labelled with superparamagnetic streptavidin microparticles and passed through a high gradient magnetic field. The percentage of CD34 + cells in the starting population was 0.18 ± 0.052%. After selection this was increased to 54.4 ± 12.3%, with a recovery of 39-74%. These workers concluded that isolation of stem cells from blood or bone marrow by MACS was a powerful technology for manipulation of the hematopoietic system. A later study by de Wynter et al, 13 again in the pre-clinical setting, tested various procedures for the purity and enrichment of CD34 + cells from bone marrow, cord blood or primed peripheral blood. MACS technology compared favorably with the other systems tested (immunomagnetic beads, panning, biotin-avidin affinity columns and FACS) giving purities of 73.8% and 81.6% when used to select CD34
+ cells from cord blood and peripheral blood respectively.
In order for MACS technology to be of broad clinical applicability it was necessary to develop a large-scale clinical grade system, and in a recent report McNiece et al 14 confirmed that high purities and good recoveries could be obtained in such a system. Thirty leukapheresis products obtained from normal volunteers who had been mobilized with filgrastim were selected using the system. In this study the starting leukapheresis products contained a median of 0.51% CD34 + (range 0.21-1.54%) cells and a median WBC of 3.0 × 10 10 (1-4.7 × 10 10 ). After selection a median purity of 95% was obtained with a median recovery of 78%. These data are comparable to those reported in this study (96.1% (range 27.4-99.4%) and 52.3% (range 15.2-146.3%)) respectively. These data are favorable compared to column adsorption selection (Cell Pro, Bothell, WA, USA). 9, 16, 17 The present study is one of the first reports of the clinical use of the large scale cell selection system (CliniMACS). The primary objective of the study was to evaluate the safety of infusion of the selected CD34 + cells as assessed by the time to hematological engraftment and the incidence of adverse events. When infused after high-dose chemotherapy, the selected cells resulted in rapid engraftment (platelet recovery 11 days, range 5-51 days, neutrophil recovery 9 days, range 5-51 days) which are similar to published values using unselected cells. Using a similar treatment schedule of cyclophosphamide, thiotepa and carboplatin, Weaver et al 18 reported median times to platelet and neutrophil engraftment of 9 days (range 0-53 days) and 9 days (range 5-26 days), respectively, while Elias et al 19 reported median times to platelet and neutrophil recovery of 12 days (range 8-134 days) and 14 days (range 10-57 days), respectively. The engraftment times obtained with the CliniMACS system, especially with respect to platelet recovery, compare well to those seen with unselected cells and CD34
+ cells selected using other technologies. 16, 17 A unique aspect of the CliniMACS system is that the antibody conjugate, once bound to the CD34 + cells, is not removed and is then infused into the patient after high-dose chemotherapy. The antibody conjugate consists of a murine monoclonal antibody (AC101) covalently bound to microbeads made of an iron-dextran complex. Allergic responses to iron-dextran when used as a therapy for anemia are widely reported in the literature. 20 , 21 The precise mechanism of action is not clear but may be due to a type III immune complex immunopathologic reaction. 21 The minimum dose of iron-dextran required to elicit an allergic response has not been established. Patients in the present study received approximately 250 g of iron-dextran and although this is much lower than the therapeutic dose it is still possible that it would be sufficient to cause allergic reactions. Review of the adverse event profile seen in patients receiving CD34
+ cells revealed no evidence of this. Although this is a small sample size these initial results suggest that infusion of the antibody conjugate is without attendant toxicity and there is no evidence of HAMA production.
The data from the present study also suggest that infusion of CD34 + cells selected via the CliniMACS system results in durable long-term engraftment although marrow repopulating cells that survived the conditioning therapy may also play a significant role. In terms of immune-reconstitution, the pattern of early recovery and 'overshoot' of CD8
+ cells compared with CD4
+ cells and a corresponding inversion of the CD4 + /CD8 + ratio within 28 days of transplant seen in the present study has been previously described in patients receiving bone marrow or peripheral blood progenitor cells. 22, 23 There were no reports of opportunistic infections during the 100 day follow-up after infusion of selected cells, although such infections have been reported following infusion of CD34 + cells selected using other systems. 24 A principal application of CD34 + cell selection is the reduction in tumor cell contamination of autografts prior to infusion to the patient. 25 The present study was not designed to investigate tumor cell content in the leukapheresis product before and after selection. However, pre-clinical studies show that use of the system can result in a 4 log depletion of tumor cells (data not shown). Theoretical calculations, based on the system performance seen in the present study, suggest a tumor cell depletion of approximately 3 logs can be expected in the clinical setting if it is assumed that there is no positive or negative preferential depletion of tumor cells. 14, 15 Finally, the consistently high purity reported here with the CliniMACS suggests that the device would also have widespread clinical application as a means of T cell depletion for allogeneic transplantation. It would also provide a suitable starting population for ex vivo expansion and gene transduction of hematopoietic progenitors.
In conclusion, the CliniMACS system can be used to select a CD34 + cell population of consistently high purity without loss of cell viability or increase in culture contamination. When these cells are infused following high-dose chemotherapy they result in rapid hematological engraftment and are not associated with any attendant toxicities. These performance characteristics suggest that the CliniMACS system may be useful as part of a tumor cell depletion regimen prior to autologous transplantation.
